Gå til hovedinnhold

Publisert 2022

Les på engelsk


Tidsskrift : BMJ Open , vol. 12 , 2022

Internasjonale standardnummer :
Trykt : 2044-6055
Elektronisk : 2044-6055

Publikasjonstype : Vitenskapelig artikkel

Bidragsytere : Hjorth, Therese; Schadow, Alena; Revheim, Ingrid; Spielau, Ulrike; Thomassen, Lise Margrete; Meyer, Klara; Piotrowski, Katja; Rosendahl-Riise, Hanne; Rieder, Anne; Varela-Tomasco, Paula; Lysne, Vegard; Ballance, Simon; Koerner, Antje; Landberg, Rikard; Buyken, Anette E.; Dierkes, Jutta

Sak : 8


Kosthold og helse


Har du spørsmål om noe vedrørende publikasjonen, kan du kontakte Nofimas bibliotekleder.

Kjetil Aune


Introduction In 2012, the estimated global prevalence
of pre-diabetes
was 280 million, and the prevalence is
expected to rise to 400 million by 2030. Oat-based
are a good source of beta-glucans,
which have been
shown to lower postprandial blood glucose. Studies to
evaluate the effectiveness of the long-term
intake of beta-glucan-
bread as part of a habitual diet among
individuals with pre-diabetes
are needed. Therefore, we
designed a multicentre intervention study in adults with
to investigate the effects of consumption
of an oat-derived
bread as part
of a normal diet on glycated haemoglobin (HbA1c) in
comparison to consumption of whole-grain
wheat bread.
Methods and analysis The CarbHealth trial is a multicentre
randomised controlled 16-week
intervention trial in participants 40–70 years of age with a
body mass index of ≥27 kg/m2 and HbA1c of 35–50 mmol/
mol. The study is conducted at four universities located
in Norway, Sweden and Germany and uses intervention
breads specifically designed for the trial by Nofima AS. The
aim is to recruit 250 participants. The primary outcome is
the difference in HbA1c between the intervention and the
control groups. The main analysis will include intervention
group, study centre and baseline HbA1c as independent
variables in an analysis of covariance model.
Ethics and dissemination The study protocol was
approved by respective ethical authorities in participating
countries. The results of the study will be communicated
through publication in international scientific journals and
presentations at (inter)national conferences.
Trial registration number NCT04994327.


Temasider tilknyttet publikasjonen